DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

January 23, 2024

Clinical Study for Patients with Newly Diagnosed Metastatic Brain Tumors

ROADS study banner

For Patients with Newly Diagnosed Metastatic Brain Tumors

If you or someone you know have been diagnosed with a metastatic brain tumor, you should be aware of the opportunity to participate in the ROADS Clinical Study. This important clinical study compares 2 FDA-cleared radiation treatments that are proven safe: GammaTile Therapy and stereotactic radiotherapy (SRT). The ROADS Clinical Study is enrolling now at participating hospitals across the country.

Roads brain graphic
Gamma Tile Official Logo - 2024

Placed at the time of brain tumor–removal surgery, GammaTile Therapy  immediately begins delivering targeted radiation to the area where the tumor  was removed, limiting radiation exposure to healthy tissue.

SRT is a precise form of external beam radiation therapy (EBRT) that is targeted directly at the brain tumor to limit radiation exposure to healthy tissue. It is typically completed on an outpatient basis in a series of 1-5 treatments.

Study participants will be randomly divided into 2 treatment groups: brain tumor removal surgery + GammaTile Therapy and brain tumor removal surgery + SRT. Following brain tumor removal surgery, clinical study participants will receive either GammaTile Therapy or SRT to the area where the tumor was. 

Study participants in both groups may have additional brain tumors that may not be suitable for surgical removal. These remaining brain tumors will be treated with SRT.

As a ROADS Clinical Study participant, you will receive a proven safe, effective treatment, and your care will be closely monitored by a physician and the medical research team. In addition, you’ll be making an important contribution to future patients with brain tumors, by helping to ensure they also receive the best possible treatment.  


Shreya Prakash photo

Contact Shreya Prakash
Clinical Research Coordinator
& Patient Navigator
shreya@endbraincancer.org

425-436-8688

contact QR code

Scan or click QR code to reach EBCI's Clinical Research Coordinator.


ebci logo

The End Brain Cancer Initiative
16150 NE 85th St, Suite #201
Redmond, WA 98052
EndBrainCancer.org


sponsor list

EBCI App QR

Scan or click the QR code to download the App now!

  • Trials & Studies
  • New Research
  • Patient & Caregiver Resources
  • Disease Information
  • Meetings & Events
  • And More!

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram